As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approach in the fight against solid tumors by leveraging the power of patients’ own… Read more »